Rohan Palekar

CIK: 0001423327

Transaction Breakdown

Open Market Buys (P)2 (10.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)13 (65.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NGNE

Neurogene Inc.

Director

ETNB

89bio, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (20 total)

NGNE
Neurogene Inc.
Feb 20, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
12.1K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Tender Offer(U)
Direct
934.3K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
120.2K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Award(A)
Direct
125K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
132.2K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
170K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
203.8K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
220K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
300K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
605K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
848K shares-
ETNB
89bio, Inc.
Aug 1, 2025
Tax Payment(F)
Direct
55.8K shares at avg. $9.16$511K
NGNE
Neurogene Inc.
Jun 12, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
12.1K shares-
ETNB
89bio, Inc.
Feb 17, 2025
Tax Payment(F)
Direct
3.2K shares at avg. $10.57$34K
ETNB
89bio, Inc.
Feb 9, 2025
Tax Payment(F)
Direct
8.9K shares at avg. $11.41$102K
ETNB
89bio, Inc.
Feb 1, 2025
Award(A)
Direct
200K shares-
ETNB
89bio, Inc.
Feb 1, 2025
Tax Payment(F)
Direct
9.6K shares at avg. $9.60$92K
ETNB
89bio, Inc.
Feb 1, 2025
Award(A)
Direct
212K shares-
ETNB
89bio, Inc.
Dec 6, 2024
Purchase(P)
Direct
5K shares at avg. $7.89$39K
ETNB
89bio, Inc.
Nov 22, 2024
Purchase(P)
Direct
10K shares at avg. $8.35$84K

		Type	Shares	Price		Ownership
Feb 20, 2026	NGNE Neurogene Inc.	Award(A) Non-Qualified Stock Option (right to buy)	12,050	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Tender Offer(U)	934,273	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	120,231	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Award(A)	125,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	132,242	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	170,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	203,750	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	220,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	300,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	605,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	848,000	-	-	Direct
Aug 1, 2025	ETNB 89bio, Inc.	Tax Payment(F)	55,836	$9.16	$511,458	Direct
Jun 12, 2025	NGNE Neurogene Inc.	Award(A) Non-Qualified Stock Option (right to buy)	12,050	-	-	Direct
Feb 17, 2025	ETNB 89bio, Inc.	Tax Payment(F)	3,249	$10.57	$34,342	Direct
Feb 9, 2025	ETNB 89bio, Inc.	Tax Payment(F)	8,946	$11.41	$102,074	Direct
Feb 1, 2025	ETNB 89bio, Inc.	Award(A)	200,000	-	-	Direct
Feb 1, 2025	ETNB 89bio, Inc.	Tax Payment(F)	9,598	$9.60	$92,141	Direct
Feb 1, 2025	ETNB 89bio, Inc.	Award(A)	212,000	-	-	Direct
Dec 6, 2024	ETNB 89bio, Inc.	Purchase(P)	5,000	$7.89	$39,450	Direct
Nov 22, 2024	ETNB 89bio, Inc.	Purchase(P)	10,000	$8.35	$83,500	Direct

1-20 of 20 transactions

About PALEKAR ROHAN

PALEKAR ROHAN (SEC CIK 0001423327) files insider reports with the SEC as Director of Neurogene Inc. (NGNE) and Chief Executive Officer of 89bio, Inc. (ETNB).

Signal8 holds 9 ownership filings by PALEKAR ROHAN, all Form 4s, filed between Nov 25, 2024 and Feb 24, 2026. Those filings report 20 transactions, from Nov 22, 2024 to Feb 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on PALEKAR ROHAN's filings is in NEW YORK, NY.

Recent filings by PALEKAR ROHAN

Feb 20, 2026: Grant or award of NGNE derivative securities (Form 4, code A).
Oct 30, 2025: Tender of shares transaction of ETNB shares (Form 4, code U).
Oct 30, 2025: Disposition to issuer transaction of ETNB derivative securities (Form 4, code D).
Oct 30, 2025: Grant or award of ETNB shares (Form 4, code A).
Oct 30, 2025: Disposition to issuer transactions of ETNB derivative securities (7 lines, Form 4, code D).

Other insiders filing for Neurogene Inc. (NGNE)

McMinn Rachel, Chief Executive Officer
Cvijic Christine Mikail, President and CFO
Woods Keith, Director
Shafer Christina, Chief Commercial Officer
Jordan Julie, Chief Medical Officer
Cobb Stuart, Chief Scientific Officer

How to read Form 4 transaction codes